SRP-1003
RNA / oligonucleotide
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06138743 NCT06138743 · Myotonic Dystrophy Type 1 Registry: NCT06138743 | 1/2 | Number of Participants with Treatment-emergent Adverse Events Over Time Through End of Study (EOS) (Single-dose phase (Part 1): Up to Day 90 (EOS); multiple-dose phase (Part 2): Up to Day 180 (EOS)) 2026-12-31 | In progress: results expected 31 Dec 2026 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Myotonic Dystrophy Type 1: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SRP-1003: this drug | Stage not on record | RNA / oligonucleotide | DMPK (dystrophia myotonica protein kinase) | not yet graded | No reviewed efficacy summary in this indication | |
| Delpacibart Etedesiran | Phase 3 | RNA / oligonucleotide | DMPK | not yet graded | No reviewed efficacy summary in this indication | |
| Pitolisant (Wakix) | Phase 2 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-670 | Phase 2 | RNA / oligonucleotide | DMPK CUG-repeat RNA | not yet graded | No reviewed efficacy summary in this indication | |
| SAR446268 | Phase 1/2 | Gene therapy / editing | DMPK | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SRP-1003 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.